• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    And subtypes I-S1 and I-S2 having additional amino acid residues at position 96 of the active site loop (b) region at positions 95-103. Mutant subtilase exhibits improved cleaning performance in detergents compared to parent enzyme.
    公开号:KR20010093171A
    申请号:KR1020017007458
    申请日:1999-12-20
    公开日:2001-10-27
    发明作者:앤더젠빌보르킴；미켈젠프랭크；한젠캠프피터；앤더젠카르스텐；뇌르가르트-매드젠매드스
    申请人:피아 스타르；노보자임스 에이/에스；
    IPC主号:
    专利说明:

    SUBTILASE ENZYMES OF THE I-S1 AND I-S2 SUB-GROUPS HAVING AN ADDITIONAL AMINO ACID RESIDUE IN ACTIVE SITE LOOP REGION}
    [2] Detergent industry enzymes have been used in cleaning preparations for over 30 years. Enzymes used in such formulations include proteases, lipases, amylases, cellulases, and other enzymes or mixtures thereof. The most important enzyme commercially is protease.
    [3] Commercially available proteases whose number increases are those that have a natural protease activity, such as DURAZYM (Novo Nordisk A / S), RELASE (Novo Nordisk A / S), MAXAPEM (Gist-Brocades NV), PURAFECT (Genencor International, Inc.).
    [4] In addition, a number of proteases are described in EP 130756 (corresponding to GENENTECH (US Reissue Patent No. 34,606 (GENENCOR)); EP 2154435 (HENKEL); WO 87/04461 (AMGEN); WO 87/05050 (GENEX); EP 260105 (GENENCOR); Thomas, Russell, and Fersht (1985) Nature 318 375-376; Thomas, Russell, and Fersht (1987) J. Mol. Biol. 193 803-813; Russel and Fersht Nature 328 496-500 (1987); WO 88/08028 (Genex); WO 88/08033 (Amgen); WO 95/27049 (SOLVAY S. A.); WO 95/30011 (PROCTER & GAMBLE COMPANY); WO 95/30010 (PROCTER & GAMBLE COMPANY); WO 95/29979 (PROCTER & GAMBLE COMPANY); US 5,543,302 (SOLVAY S. A.); EP 251 446 (GENENCOR); WO 89/06279 (NOVO NORDISK A / S); WO 91/00345 (NOVO NORDISK A / S); EP 525 610 A1 (SOLVAY); And WO 94/02618 (GIST-BROCADES N. V.).
    [5] However, although a number of useful protease variants have been described, there is still a need for new improved proteases or protease variants for a number of industrial uses.
    [6] It is therefore an object of the present invention to provide improved protease or protein engineered protease variants, especially for use in the detergent industry.
    [7] Summary of the Invention
    [8] The present inventors have discovered that at least one active site loop exhibits improved wash performance performance characteristics in detergent compositions where longer subtilisin than is currently known. Its identification is based on subtilisin variants, particularly the subtilisin 309 (BLSAVI or Savinase, which exhibits improved cleaning performance characteristics in detergent compositions compared to parent wild- ). ≪ / RTI > This is described in our prior application DK 1332/97.
    [9] Subgroups I-S1 (true " subtilisin ") and I-S2 (" subtilisin ") having at least one additional amino acid residue at position 96 (or between positions 96 and 97) It has now been found that a particular subtilase of a highly alkaline subtilisin, or variant thereof, is presently known and exhibits surprisingly improved cleaning performance compared to that described in that application.
    [10] The improved protease according to the invention is obtained by separating from natural origin or by introducing at least one further amino acid residue in the active site loop (b) between positions 96 and 97 in the wild-type subtilisin (active site definition and location See below for numbering).
    [11] Although this finding has been done in subtilisin 309, it is expected that it would be possible to produce or isolate subtilisa- or subtilase variants with similar advantages.
    [12] Furthermore, the subtilase contains a longer active site loop than the active site loop in the corresponding known wild-type subtilase, such as subtilisin 309, which can be considered to have an inserted amino acid residue between positions 96 and 97 It would be possible to specifically screen natural isolates to identify novel wildtype subtilases that exhibit excellent wash performance in detergents as compared to its most closely related known subtilisene, such as subtilisin 309.
    [13] Relevant alignment and numbering criteria are produced for the following Figures 1, 1a, 2 and 2a, and the alignment between subtilisin BPN '(BASBPN) (a) and subtilisin 309 (BLSAVI) (b) The alignment between tilysin BPN '(a) (BASBPN) and subtilisin Carlsberg (g) is shown. Figures 1A and 2A are the same as shown in WO 91/00345, but the alignment in Figures 1 and 2 was accomplished using the GAP routine of the GCG package as described below. These alignments are used herein as a reference for numbering the residues.
    [14] The seven active site loops (a) through (g) (including both indicated end amino acids)
    [15] (a) a region between amino acid residues 33 and 43;
    [16] (b) a region between amino acid residues 95 and 103;
    [17] (c) a region between amino acid residues 125 and 132;
    [18] (d) a region between amino acid residues 153 and 173;
    [19] (e) a region between amino acid residues 181 and 195;
    [20] (f) a region between amino acid residues 202 and 204;
    [21] (g) a region between amino acid residues 218 and 219
    [22] Is defined herein to encompass all of the amino acid residues.
    [23] Thus, in a first aspect, the present invention has at least one additional amino acid residue at position 96 of positions 95-103 that is a separate (i.e., more pure than 10%) active site loop (b) region, Said additional amino acid residue is associated with a subtilase enzyme of subgroup I-S1 and I-S2 corresponding to the insertion of at least one amino acid residue between position 96 and 97.
    [24] In a second aspect, the invention relates to isolated DNA sequences encoding the subtilase variants of the invention.
    [25] In a third aspect, the invention relates to an expression vector comprising a separate DNA sequence encoding a subtilase variant of the invention.
    [26] In a fourth aspect, the present invention relates to a microbial host cell transformed with an expression vector according to the third aspect.
    [27] In a further aspect, the invention relates to the production of the subtilisin enzyme of the present invention.
    [28] The enzyme of the present invention can be obtained by culturing a microorganism strain from which the enzyme is isolated and recovering the enzyme in a significantly pure form; The expression vector according to the fourth aspect is inserted into an appropriate microbial host, the host is cultured to express the desired subtilase enzyme, and the enzyme product is recovered.
    [29] In addition, the present invention relates to a composition comprising the subtilase or subtilase variants of the present invention.
    [30] Furthermore, the present invention relates to the use of the enzymes of the present invention in a number of industrial suitable uses, in particular laundry compositions comprising laundry compositions and mutagenic enzymes, in particular detergent compositions comprising mutant subtilisin enzymes.
    [31] Justice
    [32] Before describing the invention in more detail, the following terms and conventions will be defined first.
    [33] Amino acid naming
    [34] A = Ala = alanine
    [35] V = Val = valine
    [36] L = Leu = leucine
    [37] I = Ile = Ile Leucine
    [38] P = Pro = Proline
    [39] F = Phe = phenylalanine
    [40] W = Trp = tryptophan
    [41] M = Met = methionine
    [42] G = Gly = Glycine
    [43] S = Ser = serine
    [44] T = Thr = threonine
    [45] C = Cys = Cysteine
    [46] Y = Tyr = Tyrosine
    [47] N = Asn = Asparagine
    [48] Q = Gln = glutamine
    [49] D = Asp = Aspartic acid
    [50] E = Glu = Glutamic acid
    [51] K = Lys = lysine
    [52] R = Arg = arginine
    [53] H = His = histidine
    [54] X = Xaa = any amino acid
    [55] Nucleic acid naming
    [56] A = adenine
    [57] G = guanine
    [58] C = cytosine
    [59] T = thymine (DNA only)
    [60] U = uracil (RNA only)
    [61] Naming and customs for variant display
    [62] In describing various enzyme variants produced or considered in accordance with the present invention, the following nomenclature and conventions apply for convenience of reference:
    [63] The baseline skeleton was first defined by aligning the isolated wild-type enzyme with subtilisin BPN '(BASBPN).
    [64] Alignment can be obtained by GAP routines in GCG Package Version 9.1 and numbered variants using the following parameters: gap creation penalty = 8 and gap extension penalty = 8; all other parameters have their default values .
    [65] Another method is to use the known recognized alignment between subtilases such as the alignment described in WO 91/00345. In most cases the difference will not matter at all.
    [66] This alignment between subtilisin BPN '(BASBPN), subtilisin 309 (BLSAVI) and subtilisin Carlsberg (BLSCAR) is shown in Figures 1, 1a, 2 and 2a respectively. Insertion will be defined in relation to BASBPN. In Figure 1, subtilisin 309 has six deletions at positions 36, 58, 158, 162, 163 and 164 as compared to BASBPN, with subtilisin 309 having the same deletion compared to BASBPN at positions 36, 56, 159, 164, 165, and 166, respectively. In Figure 2, the subtilisin Carlsberg has one deletion at position 56 compared to BASBPN. These deletions of Figures 1, 1a, 2 and 2a are shown with an asterisk (*).
    [67] The various variants performed in the wild type enzyme are generally indicated using the following three elements:
    [68] The original amino acid position of the substituted amino acid
    [69] The notation G195E thus means that the glycine at position 195 is replaced by glutamic acid.
    [70] Where the original amino acid residue may be any amino acid residue, an abbreviated notation indicating only the position and substituted amino acid may sometimes be used.
    [71] The position of the substituted amino acid
    [72] Such indications are particularly suitable in connection with the strain (s) in homologous subtilases (see below).
    [73] The identity of the substituting amino acid residues is similar if not important.
    [74] Original amino acid position
    [75] If both the original amino acid and the substituted amino acid include all amino acids, only the position is indicated, for example: 170.
    [76] If the original amino acid and / or the substituted amino acid comprises one or more amino acids that are not all amino acids, the selected amino acid is indicated in parentheses {}.
    [77] The original amino acid position {substituted amino acid One,. . . , Substituted amino acids n}
    [78] For specific variants, specific taxonomy or alphanumeric codes are used, including codes Xaa and X to denote any amino acid residue.
    [79] substitution:
    [80] When glycine is substituted for glutamic acid at position 195:
    [81] Glyl95Glu, or G195E,
    [82] If glycine is substituted at position 195 with any amino acid residue:
    [83] Such as Glyl95Xaa or G195X or Glyl95 or G195.
    [84] If any amino acid at position 170 is substituted with serine:
    [85] It is displayed as Xaal70Ser or X170S or 170Ser or 170S.
    [86] Such indications are particularly suitable for deformation in homologous subtilases (see below). 170 Ser therefore means, for example, that both the modified Lys170Ser in BASBPN and the modified Arg170Ser in BLSAVI (see Figure 1).
    [87] For a variant in which the original amino acid and / or substituted amino acid is replaced by more than one amino acid, but not all of the amino acid, substitution of arginine with glycine, alanine serine, or threonine at position 170
    [88] Arg70 {Gly, Ala, Ser, Thr} or R170 {G, A, S, T} to refer to mutants R170G, R170A, R170S, and R170T.
    [89] fruition:
    [90] The deletion of glycine at position 195 is indicated by Glyl95 * or G195 *.
    [91] Similarly, deletion of more than one amino acid residue, such as deletion of glycine and leucine at positions 195 and 196, will be denoted by Glyl95 * + Leul96 * or G195 * + L196 *.
    [92] insertion:
    [93] For example, insertion of additional amino acids such as G195 followed by lysine may be accomplished by: Glyl95GlyLys or G195GK;
    [94] When more than one amino acid residue is inserted, for example, the insertion of Lys, Ala and Ser after G195 is: Glyl95GlyLysAlaSer or G195GKAS.
    [95] In such a case, the inserted amino acid is numbered by the addition of lower-case alphabet letters to the number of amino acid residue positions preceding the inserted amino acid residue. In this example, SEQ ID NOS: 194-196 are thus:
    [96] 194 195 196
    [97] BLSVIA - G - L
    [98] 194 195 195a 195b 195c 196
    [99] Mutant A - G - K - A - S - L
    [100] .
    [101] When the same amino acid residue as the existing amino acid residue is inserted, it is obvious that there is a diversity in naming. If, for example, glycine is inserted after glycine in this example, it will be labeled G195GG.
    [102] 194 195 196
    [103] BLSVIA - G - L
    [104] from
    [105] 194 195 195a 196
    [106] Mutation A - G - G - L
    [107] 194 194a 195 196
    [108] , The same actual change can be displayed just like A194AG. Such an example would be obvious to the skilled person, and the corresponding meaning for the representation G195GG and this type of insertion would thus include such equality of similarity.
    [109] Fill the gap:
    [110] When there is a reference deletion compared to the subtilisin BPN 'sequence used in the numbering, it is shown as 36Asp or * 36D for insertion of aspartic acid at position 36, which is the insertion at that position.
    [111] Multiple transformation
    [112] Variants containing multiple variants are separated by a plus sign, for example:
    [113] Arg170Tyr + Gly195Glu and R170Y + G195E show that arginine and glycine are substituted with tyrosine and glutamine at positions 170 and 195, respectively.
    [114] Alternatively, for example, Tyrl67 {Gly, Ala, Ser, Thr} + Argl70 {Gly, Ala, Ser, Thr} are mutants Tyr167Gly + Arg170Gly, Tyr167Gly + Arg170Ala, Tyr167Gly + Arg170Ser, Tyr167Gly + Arg170Thr, Tyr167Ala + Arg170Gly, Tyr167Ala + Arg170Ala , Tyrl67Ala + Argl70Ser, Tyrl67Ala + Argl7OThr, Tyrl67Ser + Argl70Gly, Tyrl67Ser + Argl70Ala, Tyrl67Ser + Argl70Ser, Tyrl67Ser + Argl70Thr, Tyrl67Thr + Argl70Aly, Tyrl67Thr + Argl70Ala, Tyrl67Thr + Argl70Ser and Tyrl67Thr + Argl70Thr.
    [115] This nomenclature can be used for example, Tyrl 67 {Gly, Ala, Ser, Thr} + Argl 70, which represents the substitution of a positive charge (K, R, H), a negative charge (D, E) Conservative amino acid modifications at {Gly, Ala, Ser, Thr} are particularly suitable in connection with modifications aimed at substitution, replacement, insertion or deletion of amino acid residues having certain general characteristics. See the " Detailed Description of the Invention " section for further details.
    [116] Protease
    [117] Enzymes that cleave the amide bond of a protein substrate are classified as proteases or (compatible) peptidases (Walsh, 1979, Enzymatic Reaction Mechanisms, W. H. Freeman and Company, San Francisco, Chapter 3).
    [118] Number of amino acid positions / residues
    [119] Unless otherwise stated, the amino acid numbering used herein corresponds to the numbering of the subtilase BPN '(BASBPN) sequence. Further techniques of the BPN ' sequence are shown in Figures 1 and 2 or Siezen et al., Protein Engng. 4 (1991) 719-737.
    [120] Serine protease
    [121] Serine proteases are enzymes that catalyze the hydrolysis of peptide bonds and have essential serine residues at their active sites (White, Hadler and Smith, 1973 "Princeples of Biochemistry," Fifth Edition, McGraw-Hill Book Company, pp. 271-272) .
    [122] Bacterial serine proteases have molecular weights ranging from 20,000 to 45,000 dalton. It is inhibited by diisopropyl fluorophosphate. It hydrolyzes simple terminal esters and is similar in activity to eukaryotic chymotrypsin, also a serine protease. In a narrower sense, the alkaline proteases encompassing the subgroups reflect a high optimum pH of some serine proteases at pH 9.0-11.0 (see Priest (1997) Bacteriological Rev. 41 711-753 for review).
    [123] Subtilase
    [124] Subgroups of serine proteases, termed subtilase, are described by Siezen et al., Protein Engng. 4 (1991) 719-737 and Siezen et al., Protein Science 6 (1997) 501-523. It was defined by homology analysis of more than 170 amino acid sequences of serine proteases previously named with subtilisin-like proteases. Subtilisin has previously been defined as a serine protease produced by gram-positive bacteria or fungi and is currently defined as a subgroup of subtilases according to Siezen et al. A wide variety of subtilases have been identified and the amino acid sequences of many subtilases have been determined. A more detailed description of such subtilases and their amino acid sequences can be found in Siezen et al. (1997).
    [125] One subgroup of subtilase I-S1 or " sedated subtilisin " is subtilisin 168 (BSS168), subtilisin BPN ', subtilisin Carlsberg Novo Nordisk A / S) and subtilisin DY (BSSDY).
    [126] A further subgroup, I-S2, or highly alkaline subtilisin of the subtilase is described by Siezen et al. (Above). Subgroup I-S2 protease is described as highly alkaline subtilisin, and subtilisin PB92 (BAALKP) (MAXACAL , Gist-Brocades NV), Subtilisin 309 (SAVINASE , NOVO NORDISK A / S), subtilisin 147 (BLS147) (ESPERASE , NOVO NORDISK A / S) and alkaline erastase YaB (BSEYAB).
    [127] Abbreviation list for subtilase
    [128] I-S1
    [129] (Subtilisinamylosacchariticus), BSAPRJ (subtilisin J), BSAPRN (subtilicin NAT), BMSAMP (mesenceteric peptidase),
    [130] Subtilisin BPN ', BASBPN
    [131] Subtilisin DY, BSSDY,
    [132] Subtilisin Carlsberg, BLSCAR (BLKERA (Keratinase), BLSCA1, BLSCA2, BLSCA3),
    [133] BSSPRC, serine protease C
    [134] BSSPRD, serine protease D
    [135] I-S2
    [136] Subtilis Shin Sendai, BSAPRS
    [137] Subtilisin ALP 1, BSAPRQ,
    [138] Subtilisin 147, Esperase BLS147 (BSAPRM (SubtilisinPRM), BAH101),
    [139] Subtilisin 309, Savinase , BLS309 / BLSAVI (BSKSMK (M-protease), BAALKP (subtilisin PB92, Bacillus alkalophilic alkaline protease), BLSUBL (subtilicin BL)),
    [140] Alkaline estrases YaB, BYSYAB,
    [141] "SAVINASE "
    [142] SAVINASE Are sold by NOVO NORDISK A / S. This is B.leutus- derived subtilisin 309 and is unique only to BAALKP (N87S, see FIG. 1 herein). SAVINASE Has an amino acid sequence represented by b) in Fig.
    [143] ≪ RTI ID =
    [144] The term " moiety subtilase "Lt; / RTI > (1991 and 1997). For a more detailed description, see the description of "Subtilase" above. The moat subtilase is also a subtilase isolated from natural origin and the subsequent modification is carried out while maintaining the properties of subtilisin. Alternatively, the term " subtilase " is termed " wild type subtilase ".
    [145] Modification of Subtilase Variants
    [146] The term " modification ", as used herein, is defined to include chemical modification of the subtilase as well as genetic manipulation of the DNA encoding the subtilase. Deformation may be replacement, substitution, deletion and / or insertion of amino acid side chains within or within the amino acid of interest.
    [147] Subtilase variant
    [148] The term subtilase mutant or mutated subtilase in the context of the present invention refers to a subtilase produced by a living organism that expresses a mutant gene derived from a parent that produces the corresponding parent enzyme with the original breast milk Wherein the breast milk was mutated to produce a mutant gene in which the mutated subtilase protease is produced when expressed in a suitable host.
    [149] Homologous subtilase sequence
    [150] For modification to obtain the subtilisin variants of the present invention, here, the specific active site loop region and the SAVINASE The amino acid insertion in the loop of the subtilase is identified.
    [151] However, the present invention is not limited to the modification of this specific subtilase, But also to other parent (wild type) subtilases having a primary structure homologous to the primary structure of the parent. In this context, homology between two amino acid sequences is described by the "identity" criterion.
    [152] To determine the degree of identity between two subtilases, the GAP routines of the GCG package version 9.1 can be applied using the same settings (see below). The result from this routine is a calculation of the " percent identity " between two sequences in addition to the amino acid sequence.
    [153] It is readily apparent to those skilled in the art to identify suitable homologous subtilases and corresponding homologous active site loop regions that may be modified in accordance with the present invention based on this technique.
    [154] Cleaning performance
    [155] For example, during washing or light surface washing, the ability of the enzyme to catalyze the decomposition of various naturally occurring substrates present on the object to be laundered is often referred to as its cleaning power, cleaning power, washing power or washing performance. Through this application, the term wash performance will be used to cover this feature.
    [156] Isolated DNA sequence
    [157] The term " isolated ", when used in a DNA sequence molecule, indicates that the DNA sequence is isolated in its natural genetic environment and thus is free of other exogenous or unwanted coding sequences and is suitable for use in genetically engineered protein production . Such isolated molecules are isolated from its natural environment and contain cDNA and genomic clones. Isolated DNA molecules of the present invention typically have no other genes linked but may contain native 5 'and 3' non-translated regions such as promoters and terminators. Identification of the linked regions will be apparent to those of ordinary skill in the art (see, for example, Dynan and Tijan, Nature 316 : 74-78, 1985). The term " isolated DNA sequence " may alternatively be termed " cloned DNA sequence ".
    [158] Isolated protein
    [159] When applied to a protein, the term " isolated " refers to a protein separated from its natural environment.
    [160] In a preferred form, the isolated protein is significantly absent from other proteins, particularly homologous proteins (i.e., "homologous impurities" (see below)).
    [161] When determined by SDS-PAGE, the isolated protein is more pure than 10%, preferably more than 20%, more preferably more than 30% pure. In addition, when determined by SDS-PAGE, it is preferred that it is in a high-purity form, i.e. more than 40%, more than 60%, more than 80% more pure, more preferably more than 95% It is desirable to provide a more pure protein. The term " isolated protein " is alternatively termed " purified protein ".
    [162] Homologous impurity
    [163] The term " homologous impurity " refers to any impurity (e.g., a polypeptide other than a polypeptide of the invention) derived from a homologous cell in which the polypeptide of the present invention was originally obtained.
    [164] Obtained from
    [165] The term " obtained from " when used herein in connection with a particular microbial origin means a polynucleotide and / or polypeptide produced by a cell into which a gene of a particular origin or origin thereof has been inserted.
    [166] temperament
    [167] The term " substrate " used in reference to a substrate for a protease should be interpreted in its widest form, including compounds containing at least one peptide bond susceptible to hydrolysis by subtilisin proteases.
    [168] product
    [169] The term " product " used in connection with the protease enzymatic reaction should be interpreted in the context of the present invention as including products of hydrolysis involving the subtilase protease. The product may be the substrate of the subsequent hydrolysis reaction.
    [1] The present invention relates to a novel subtilase enzyme of subgroup I-S1 and I-S2 having at least one additional amino acid residue at position 96 of position 95 to 103 which is the active site loop (b) region. This protease is detergent; When used in laundry and detergent compositions, exhibit excellent or improved cleaning performance. The present invention provides a gene encoding an expression of the enzyme when inserted into a suitable host cell or organism; To such host cells which are capable of being transformed therewith and capable of expressing said enzyme variants, and to the production of novel enzymes.
    [170] FIG. 1 is a graph showing the relationship between subtilisin BPN '(a) and Savinase (b). < / RTI >
    [171] FIG. 1A is a schematic representation of a subtilisin BPN 'and Savinase < RTI ID = 0.0 > Lt; / RTI >
    [172] Figure 2 shows the alignment between subtilisin BPN 'and subtilisin Carlsberg using GAP routines.
    [173] Figure 2a shows the alignment between subtilisin BPN 'and subtilisin Carlsberg as taken from WO 91/00345.
    [174] Figure 3 shows the three-dimensional structure of Savinase (Protein data bank (PDB) entry 1SVN). In the figure, the active site loop (b) is displayed.
    [175] The subtilase of the present invention has at least one additional amino acid residue at position 96 of the active site loop region at positions 95 to 103 on the first side so that said additional amino acid residue is at least one amino acid residue between positions 96 and 97 (I.e., less than 10% pure) subtilase enzyme of subgroups I-S1 and I-S2, corresponding to the insertion of the subtilase.
    [176] In other words, the subtilase of the present invention is characterized by containing an active site loop (b) region of more than 9 amino acid residues, wherein the additional amino acid residues are located at positions 96 and < RTI ID = 0.0 > 97, or may be considered to be inserted.
    [177] The subtilase of the first aspect of the present invention is a parent or wild type subtilase identified and isolated from nature.
    [178] Such wild-type subtilases are specifically screened by standard techniques known in the art.
    [179] A preferred means of doing this is to specifically PCR amplify a region of DNA known to encode the active site loop region of a number of different microorganisms, preferably of the Bacillus strain-derived subtilase .
    [180] Subtilases are a group of conserved enzymes in that their DNA and amino acid sequences are homologous. Thus, it is possible to produce relatively specific primers tangent to both sides of the active site loop.
    [181] One means of doing this is to perform the alignment of the different subtilases (e.g., Siezen et al. Protein Science 6 (1997) 501-523). From this, it is easy for a person skilled in the art to produce a PCR primer which is in contact with both sides of the active site loop corresponding to the active site loop (b) between the amino acid residues 95 to 103 in any one of group I-S1 and I-S2 derived from BLSAVI will be. When such a PCR primer is used to amplify DNA from a number of different microorganisms, preferably different Bacillus strains, and DNA sequencing of the amplified PCR fragment, for example, compared to BLSAVI, Can be identified, and insertions can be considered to lie between positions 96 and 97. In addition, Once the partial DNA sequence has been identified with the subtilase strain of interest, it is an easy task for those skilled in the art to complete, express and purify such a subtilase of the present invention.
    [182] However, it can be predicted that the subtilase enzyme of the present invention is mainly a mutant of the subtilase.
    [183] Thus, in an embodiment, the present invention relates to a subtilase enzyme isolated according to the first aspect of the present invention, wherein said subtilase enzyme has at least one amino acid between amino acid residues 96 and 97, Lt; RTI ID = 0.0 > (b). ≪ / RTI >
    [184] The subtilase of the present invention exhibits excellent washing performance in detergents and exhibits improved washing performance compared to its closest related subtilase such as subtilisin 309 if the enzyme is a prepared variant.
    [185] The different subtilase products exhibit different washing performance in different types of detergent compositions. The subtilisers of the present invention have improved cleaning performance compared to the nearest homologous species in many of these different types of detergent compositions.
    [186] Preferably the subtilase enzyme of the present invention in the detergent composition shown here in Example 3 has improved washing performance compared to its closest counterpart (see below).
    [187] Determining whether the given subtilase amino acid sequence is within the scope of the present invention (whether the subtilase sequence is the parent wild-type subtilase sequence or the subtilase variant sequence produced by any other method than inducing site-specific mutagenesis) To this end, the following process:
    [188] i) aligning the subtilase sequence with the amino acid sequence of subtilisin BPN '(see "Definition" section hereinbefore);
    [189] ii) the active site of subtilisin BPN 'comprising the amino acid residues 95 to 103 (including the amino acids at both ends) of the subtilisin BPN' Based on the alignment of step i) in the subtilase sequence corresponding to the loop (b) Identifying the active site loop (b);
    [190] iii) whether the active site loop (b) in the subtilase sequence identified in step ii) is longer than the active site loop in the corresponding BLSAVI and whether the extension inserts at least one amino acid between positions 96 and 97 A step of determining whether or not to respond can be used.
    [191] If so, the observed subtilase is a subtilase within the scope of the present invention.
    [192] The alignment performed in step i) above is performed using the GAP routine as described above.
    [193] It is easy for those skilled in the art to identify the active site loop (b) in the subtilase based on this description and determine whether the subtilase in question is within the scope of the present invention. If the mutant is produced by site-specific mutagenesis, it is of course known that the subtila is within the scope of the present invention.
    [194] The subtilase variants of the present invention are prepared by DNA shuffling of standard techniques known in the art, such as site specific mutagenesis / random mutagenesis, or different subtillase sequences. For further details, see the section entitled " Production of Subtilase Mutants " and Materials and Methods section herein (see above).
    [195] In a further embodiment,
    [196] 1. An isolated subtilase enzyme according to the invention, wherein said at least one inserted amino acid residue is selected from the group comprising T, G, A and S;
    [197] 2. The isolated subtilase enzyme according to the invention, wherein said at least one inserted amino acid residue is selected from the group consisting of D, E, H, K and R, more preferably D, E, K and R Wherein the band is selected from the group of amino acid residues;
    [198] 3. The isolated subtilase enzyme according to the invention, wherein said at least one inserted amino acid residue is a hydrophilic amino acid residue comprising C, N, Q, S and T, more preferably N, Q, S and T An enzyme selected from the group consisting of:
    [199] 4. An isolated subtilase enzyme according to the invention, wherein said at least one inserted amino acid residue is selected from the group of small hydrophobic amino acid residues comprising A, G and V;
    [200] 5. The isolated subtilase enzyme according to the invention, wherein said at least one inserted amino acid residue is selected from the group consisting of F, I, L, M, P, W and Y, more preferably F, I, ≪ RTI ID = 0.0 > and / or < / RTI >
    [201] In a further embodiment, the invention relates to a separate subtilase enzyme according to the invention, wherein the insertion between positions 96 and 97 comprises at least two amino acids when compared to the active site loop of the corresponding BLSAVI.
    [202] In a further embodiment,
    [203] (In BASBPN numbering)
    [204] X96X {T, G, A, S}
    [205] X96X {D, E, K, R}
    [206] X96X {H, V, C, N, Q}
    [207] X96X {F, I, L, M, P, W, Y}
    [208] Or more specifically for subtilisin 309 and myelinated subtilases such as BAALKP, BLSUBL, and BSKSMK
    [209] L96LA
    [210] L96LT
    [211] L96LG
    [212] L96LS
    [213] L96LD
    [214] L96LE
    [215] L96LK
    [216] L96LR
    [217] L96LH
    [218] L96LV
    [219] L96LC
    [220] L96LN
    [221] L96LQ
    [222] L96LF
    [223] L96LI
    [224] L96LL
    [225] L96LM
    [226] L96LP
    [227] L96LW
    [228] L96LY
    [229] ≪ RTI ID = 0.0 > and / or < / RTI > the at least one insert.
    [230] Furthermore, the present invention provides multiple insertion at position 96,
    [231] L96LA + A98T
    [232] L96LG + A98T + S103T
    [233] L96LG + A98T + Y167A
    [234] L96LG + G100S
    [235] L96LG + G100S + Y167A
    [236] L96LG + Y167A
    [237] L96LG + S99T + S101A
    [238] L96LG + A98G + S99G + S101T + S103T
    [239] ≪ RTI ID = 0.0 > and / or < / RTI >
    [240] It is well known in the art that the so-called conservative substitution of one amino acid residue with a similar amino acid residue predicts only minor changes in the properties of the enzyme.
    [241] Table III below lists conservative amino acid substitution groups.
    [242] Table 3
    [243] Conservative amino acid substitution
    [244] General characteristics Amino acid
    [245] Basic (positive charge) K = Lysine
    [246] H = histidine
    [247] Acid (Negative charge) E = Glutamic acid
    [248] D = aspartic acid
    [249] Polarity Q = glutamine
    [250] N = asparagine
    [251] Hydrophobic L = leucine
    [252] I = isoleucine
    [253] V = Balin
    [254] M = methionine
    [255] Aromatic F = phenylalanine
    [256] W = tryptophan
    [257] Y = tyrosine
    [258] Small G = glycine
    [259] A = alanine
    [260] S = serine
    [261] T = threonine
    [262] According to this principle, subtilase variants containing conservative substitutions such as G97A + A98S + S99G, G97S + A98AT + S99A are expected to exhibit properties that are not significantly different from each other.
    [263] Identifying suitable conservative variations for such mutants to obtain other subtilase variants exhibiting similar improved wash performance based on the subtilase variants disclosed and / or exemplified herein may be readily accomplished by those skilled in the art to be.
    [264] According to the present invention, the subtilase of the present invention can be obtained by isolating the novel enzyme of the present invention from natural or various artificial production, and in sub-groups I-S1 and < RTI ID = 0.0 > I-S2, in particular subgroup I-S2.
    [265] Maintaining the characteristics of BSS168 (BSSAS, BSAPRJ, BSAPRN, BMSAMP), BASBPN, BSSDY, BLSCAR (BLKERA, BLSCA1, BLSCA2, BLSCA3), BSSPRC and BSSPRD or subgroup I-S1 with respect to subgroup I- It is desirable to select a moiety from the group comprising the functional variants thereof.
    [266] (BSAPRM, BAH101), BLSAVI (BSKSMK, BAALKP, BLSUBL), BYSYAB and BSAPRS or their functional variants retaining the characteristics of subgroup I-S2, in relation to subgroup I-S2 derived variants It is preferred to select the moiety from the group.
    [267] Particularly, the above-mentioned subtilase is BLSAVI (SAVINASE NOVO NORDISK A / S), and the preferred subtilase variants of the present invention are therefore SAVINASE Lt; / RTI >
    [268] The invention also encompasses any one of the subtilases of the present invention in combination with any of the other variants of its amino acid sequence. In particular, combinations with other variants known in the art that provide improved properties to the enzyme are predicted. The art describes a number of subtilase variants with different improved properties and many variants are described in the " Background of the Invention " section (see above). The reference is hereby incorporated herein by reference for the identification of subtilase variants which can be advantageously combined with the subtilase variants of the present invention.
    [269] Such combinations include position: 222 (improved oxidation stability), 218 (improved thermal stability), substitution within the Ca-binding site to stabilize the enzyme, such as position 76 and many others evident from the prior art.
    [270] In a further embodiment, the subtilase variants of the present invention are:
    [271] The present invention is advantageously combined with one or more variations in any one of the following numbers: 27, 36, 57, 76, 87, 97, 101, 104, 120, 123, 167, 170, 206, 218, 222, 224, 235,
    [272] Specifically, the following BLSAVI, BLSUBL, BSKSMK, and BAALKP variants:
    [273] K27R, * 36D, S57P, N76D, S87N, G97N, S101G, S103A, V104A, V104I, V104N, V104Y, H120D, N123S, Y167, R170, Q206E, N218S, M222S, M222A, T224S, K235L and T274A I think.
    [274] S101G + V104N, S87N + S101G + V104N, K27R + V104Y + N123S + T274A, N76D + S103A + V104I or N76D + V104A or other combinations of these mutants (V104N, S101G, K27R, V104Y, N123S, T274A, N76D, V104A) Wherein any one of the variants is combined with one or more of the variants exhibits improved properties.
    [275] Further variants of the main aspects of the present invention are described as variants at positions 129, 131, 133 and 194, preferably as 129K, 131H, 133P, 133D and 194P variants and most preferably as P129K, P131H, A133P , A133D, and A194P variants. Any of these modifications are expected to provide a higher level of expression of the subtilase variants of the invention in its production.
    [276] Thus, further embodiments of the present invention relate to variants according to the present invention wherein the variants are selected from the group comprising.
    [277] Production of Subtilase Variants
    [278] A number of methods are known in the art for cloning subtilases of the present invention and introducing insertions into genes (e. G., Subtilase genes) (see references cited in the Background section).
    [279] In general, a standard method of cloning a gene and introducing an insert into the gene (random and / or site-specific) is used to obtain the subtilase variants of the present invention. Other techniques of suitable techniques can be found in the Examples hereinbelow (see Sambrook et al. (1989) Molecular cloning: A laboratory manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY; Ausubel, FM et al. (eds.) "Current Protocols in Mollecular Biology", John Wiley and Sons, 1995; Harwood, CR, and Cutting, SM (eds.) "Molecular Biological Methods for Bacillus" 34946 is a reference.
    [280] In addition, the subtilase mutants of the present invention are produced by standard techniques for artificial production of variants such as DNA shuffling of different subtillases (WO 95/22625; Stemmer WPC, Nature 370: 389-91 (1994)) do. For example, Savinase (B) an active site longer than the loop; and (b) at least one naturally-occurring subtilase comprising a loop region. Will provide the subtilase variants according to the invention after screening for the subsequent improved wash performance variants.
    [281] Expression vector
    [282] The recombinant expression vector comprising the DNA construct encoding the enzyme of the present invention may conveniently be any vector which will carry out the recombinant DNA procedure.
    [283] The choice of vector will often depend on the host cell from which it is introduced. Thus, a vector is an autonomous replication vector whose replication is independent of chromosomal replication, i. E., A vector that exists as an extrachromosomal gene, for example, a plasmid. Alternatively, the vector may be introduced into the host cell so that all or part of it is inserted into the host cell genome and replicated along with the inserted chromosome.
    [284] The vector is preferably an expression vector in which the DNA sequence encoding the enzyme of the present invention is operably linked to an additional fragment necessary for DNA transcription. Generally, the expression vector is derived from a plasmid or viral DNA, or contains both of the factors. The term " operably linked " indicates that the fragment is arranged to serve its intended purpose, e.g., to initiate transcription in the promoter and to continue in the DNA sequence encoding the enzyme.
    [285] A promoter may be any DNA sequence that exhibits transcriptional activity in a host cell of choice and may be derived from a gene encoding a homologous or non-coding protein in the host cell.
    [286] Examples of suitable promoters for use in bacterial hosts are promoters or phage of Bacillus stearothermophilus maltogenic amylase gene, Bacillus licheniformis alpha -amylase gene, Bacillus amyloliquefaciens alpha -amylase gene, Bacillus subtilis alkaline protease gene, or Bacillus pumilus xylosidase gene. P R or P L promoter or E. coli lac , trp or tac promoter.
    [287] The DNA sequence encoding the enzyme of the present invention is also operably linked to a suitable terminator if necessary.
    [288] The recombinant vector of the present invention further comprises a DNA sequence that allows the vector to replicate within the host in question.
    [289] The vector may also contain a selectable marker, e. G., A gene whose product is complementary to a deficiency in the host cell, or a gene encoding a gene encoding a resistance or heavy metal resistance to antibiotics such as, for example, kanamycin, chloramphenicol, erythromycin, tetramycin, spectinomycin, Gene.
    [290] In order to induce the enzyme of the present invention into the secretory pathway of the host cell, a secretory signal sequence (also known as a leader sequence, a prepro sequence, or a prese sequence) is provided in the recombinant vector. The secretory signal sequence is linked to the enzyme coding sequence to match the frame. The secretory signal sequence is generally located 5 'of the DNA sequence encoding the enzyme. The secretory signal sequence is normally derived from a gene that is associated with an enzyme or that encodes another secreted protein.
    [291] Ligation into a DNA sequence encoding the enzyme, promoter and optionally a terminator and / or secretory signal sequence, respectively, or to insert these sequences into a suitable vector containing the information necessary for cloning or insertion, (E. G., Sambrook et al., Cited above).
    [292] Host cell
    [293] The DNA sequence encoding the enzyme that is introduced into the host cell may be homologous or heterologous to the host cell in question. If it is homologous to the host cell, that is, it is naturally produced by the host cell, it will typically be operably linked to another promoter sequence or, if applicable, another secretory signal sequence and / or terminator sequence than its natural environment . The term " homologous " is intended to include a DNA sequence encoding a native enzyme in the host organism in question. The term " non-invasive " is intended to include DNA sequences that are not naturally expressed by the host cell. Thus, the DNA sequence is derived from another organism or is a synthetic sequence.
    [294] The DNA construct of the present invention or the host cell into which the recombinant vector is introduced may be any cell capable of producing the enzyme and includes higher eukaryotic cells including bacteria, yeast, fungi and plants.
    [295] Examples of bacterial host cells capable of producing the enzyme of the present invention in culture include B. subtilis, B. licheniformis, B. lentus, B. brevis, B. stearothermophilus, B. alkalophilus, B. amyloliquefaciens, B. coagulans, B. such as Bacillus strains such as B. circulans, B. lautus, B. megatherium , or B. thuringiensis , Gram-positive bacteria such as Streptomyces strains such as S. lividans or S. murinus, or Gram-negative bacteria such as Escherichia coli .
    [296] Bacterial transformation is accomplished using protoplast transformation, electroporation, conjugation, or by means of means known in the art (see Sambrook et al. Supra).
    [297] When expressing an enzyme in a bacterium such as E. coli, the enzyme is typically retained in the cytoplasm as insoluble granules (known as inclusion bodies) or transferred to the periplasmic space by a bacterial secretory sequence. In the former case, the cells are dissolved, the granules are recovered and denatured, and then the enzyme is refolded by the dilution of the denaturing agent. In the latter case, the enzyme destroys the cells, for example, by sonication or osmotic shock, causing the contents of the surrounding space to be ejected, recovering the enzyme and recovering it from the surrounding space.
    [298] When the enzyme is expressed in gram-positive bacteria such as Bacillus or Streptmyces strains, the enzyme is retained in the cytoplasm or transferred to the extracellular medium by the bacterial secretory sequence. In the latter case, the enzyme is recovered from the culture as described below.
    [299] Production method of subtilase
    [300] The present invention provides a method for producing a separated enzyme according to the present invention wherein a suitable host cell transformed with the DNA sequence encoding the enzyme is cultured under conditions permitting the production of the enzyme and the resulting enzyme recovered from the culture .
    [301] An expression vector comprising a DNA sequence encoding an enzyme is transformed into an inactivated host cell to enable the non-equibiral recombinant production of the enzyme of the present invention.
    [302] Thus, it is possible to produce a fixed detached subtilase composition characterized by the absence of homologous impurities.
    [303] In this context, a homologous impurity also refers to any impurity (for example, a polypeptide other than the enzyme of the present invention) derived from the homologous cell from which the enzyme of the present invention was first obtained.
    [304] The medium used for culturing the transformed host cells may be any conventional medium suitable for growing host cells of interest. The expressed subtilase is conveniently secreted into the culture medium, and the cells are separated from the medium by centrifugation or filtration, and the protein composition is precipitated by a salt such as ammonium sulfate, followed by chromatography such as ion exchange resin, affinity chromatography, ≪ RTI ID = 0.0 > and / or < / RTI >
    [305] Use of the subtilase variants of the present invention
    [306] The subtilase variants of the present invention are used in many industrial applications, especially in the detergent industry.
    [307] In addition, the present invention relates to an enzyme composition comprising a subtilase variant of the present invention.
    [308] A summary of preferred enzyme compositions corresponding to the preferred industrial applications follows.
    [309] This summary is not intended to be exhaustive in any way to enumerate the proper applications of the subtilase variants of the present invention. The subtilase variants of the present invention can be used in other industrial applications known in the art, including the use of proteases, particularly subtilases.
    [310] A detergent composition comprising a mutant enzyme
    [311] The present invention includes such compositions comprising washing of the mutant enzymes of the invention and their use in detergent compositions and mutant subtilase enzymes. Such cleaning and detergent compositions are well known in the art and are described in WO 96/34946; WO 97/07202; WO 95/30011 is a reference to further cleaning of suitable detergent compositions and detergent compositions.
    [312] Furthermore, the following Examples (s) describe improvement of the cleansing ability to the subtilase variants of the present invention.
    [313] Detergent composition
    [314] The enzyme of the present invention is added to the detergent composition and thus becomes a constituent of the detergent composition.
    [315] The detergent compositions of the present invention may be formulated as, for example, detergent or machine laundry detergent compositions comprising a pretreatment laundry additive composition of rugged fabrics and a fabric softener composition comprising a rinse agent, , Or prepared by dishwashing or mechanical dishwashing operation.
    [316] In a specific aspect, the present invention provides a detergent additive comprising the enzyme of the present invention. In addition to the detergent composition, the detergent additive may also be selected from the group consisting of protease, lipase, cutinase, amylase, carbohydrase, cellulase, pectinase, mannanase, arabinase, galactanase, xylanase, And one or more other enzymes such as an enteric and / or peroxidase.
    [317] In general, the nature of the selected enzyme should be compatible with the selected detergent (i.e., optimal-pH, compatibility with other enzymes and non-enzymatic components, etc.), and the enzyme should be present in an effective amount.
    [318] Proteases : Suitable proteases include those of animal, plant or bacterial origin. Bacterial origin is preferred. Chemically modified or protein engineered mutations. The protease may be a serine protease or a metalloprotease, preferably an alkaline microorganism protease or a trypsin-like protease. Examples of alkaline proteases include, but are not limited to, subtilisin, especially subtilisins from Bacillus , such as subtilisin Novo, subtilisin Carlsberg, subtilisin 309, subtilisin 147 and subtilisin 168 (WO 89/06279 Lt; / RTI > Examples of trypsin-like proteases are trypsin (e.g. of the porcine or bovine origin) and the Fusarium proteases described in WO 89/06270 and WO 94/25583.
    [319] Examples of useful proteases include variants described in WO 92/19729, WO 98/20115, WO 98/20116 and WO 98/34946, especially the following positions: 27, 36, 57, 76, 87, 97, 101, 104, 120 , 123, 167, 170, 194, 206, 218, 222, 224, 235, 274.
    [320] Preferred commercially available commercially available protease enzymes Alcalase TM, Savinase TM, Primase TM , Duralase TM, Esperase TM, Kannase TM (Novo Nordisk A / S), Maxatase TM, Maxacal TM, Maxapem TM, Properase TM, Purafect TM, Purafect OxP TM , FN2 TM and FN3 TM (Genencor International Inc.).
    [321] Lipases : Suitable lipases include bacteria or fungal origin. Chemically modified or protein engineered mutations. Examples of useful lipases are Humicola (synonym Thermomyces ), for example H. lanuginosa ( T. lanuginosus ) described in EP 258 068 and EP 305 216 or H. insolens- derived lipase described in WO 96/13580, Pseudomonas lipase, For example P. alcaligenes or P. pseudoalcaligenes (EP 218 272), P. cepacia (EP 331 376), P. stutzeri (GB 1,372,034), P. fluorescens, Pseudomonous sp. SD 705 (WO 95/06720 and WO 96 / 27002), P. wisconsinesis derived lipase, Bacillus lipase, e.g., B. subtilis (Dartois et al. ( 1993), Biochemica et Biophysica Acta, 1131, 253-360), B. stearothermophilus (JP 64/744992) or B . < / RTI & gt ; pumilus (WO 91/16422).
    [322] Other examples are described in WO 92/05249, WO 94/01541, EP 407 225, EP 260 105, WO 95/35381, WO 96/00292, WO 95/30744, WO 94/25578, WO 95/14783, WO 95/22615 , WO 97/04079 and WO 97/07202.
    [323] Preferred commercially available lipase enzymes include Lipolase TM and Lipolase Ultra TM (Novo Nordisk A / S).
    [324] Amylase : Suitable amylases (alpha and / or beta) include bacterial or fungal origin. Chemically modified or protein engineered mutations. Amylases include, for example, [alpha] -amylases obtained in certain strains of B. licheniformis described in more detail in, for example, Bacillus , for example GB 1,296, 839.
    [325] Examples of useful amylases include those described in WO 94/02597, WO 94/18314, WO 96/23873, and WO 97/43424, particularly those having the following positions: 15, 23, 105, 106, 124, 128, 133, 154 , 156, 181, 188, 190, 197, 202, 208, 209, 243, 264, 304, 305, 391, 408 and 444.
    [326] Commercially available amylases are Duramyl ™ , Termamyl ™ , Fungamyl ™ and BAN ™ (Novo Nordisk A / S), Rapidase ™ , and Purastar ™ (from Genencor International Inc.).
    [327] Cellulases : Suitable cellulases include those of bacterial or fungal origin. Chemically modified or protein engineered mutations. Suitable cellulases are selected from the group consisting of Humicola insolens, Myceliophthora thermophila and Fusarium oxysporum as disclosed in Bacillus, Pseudomonas, Humicola, Fusarium, Thielavia, Acremonium derived cellulases such as those described in US 4,435,307, US 5,648,263, US 5,691,178, US 5,776,757 and WO 89/09259 It is a cellulase produced.
    [328] Particularly suitable cellulases are alkaline or neutral cellulases with color protection benefits. Examples of such cellulases are the cellulases described in EP 0 495 257, EP 0 531 372, WO 96/11262, WO 96/29397, WO 98/08940. Other examples of cellular variants are described in WO 94/07998, EP 0 531 315, US 5,457,046, US 5,686,593, US 5,763,254, WO 95/24471, WO 98/12307 and PCT / DK98 / 00299.
    [329] Commercially available cellulases include Celluzyme ™ , Carezyme ™ (Novo Nordisk A / S), Clazinase ™ , Puradax HA ™ (Genencor International Inc.) and KAC-500 (B) ™ (Kao Corporation).
    [330] Peroxidase / Oxidase : Suitable peroxidase / oxidase includes plant, bacterial or fungal origin. Chemically modified or protein engineered mutants. Examples of useful peroxidases include peroxidases derived from C. cinereus such as those described in Coprinus , for example WO 93/24618, WO 95/10602, and WO 98/15257, and variants thereof.
    [331] Commercially available peroxidases include Guardzyme TM (Novo Nordisk A / S).
    [332] The detergent enzyme is included in the detergent composition by adding an individual additive containing one or more enzymes or by adding a combination additive comprising both of these enzymes. The detergent additives of the present invention, i.e., individual additives or combination additives, can be prepared, for example, as granules, liquids, slurries, and the like. Preferred detergent additive formulations are granules, especially non-dust granules, liquids, in particular stabilizing liquids, or slurries.
    [333] Non-dust granules are produced, for example, as described in US 4,106,991 and 4,661,452, and optionally coated by methods known in the art. Examples of wax-like coating materials include poly (ethylene oxide) products (polyethylene glycol, PEG) having an average molecular weight of 1000 to 20,000; Ethoxylated n-phenol having 16 to 50 ethylene oxide units; Alcohol is a farnes alcohol containing 12 to 20 carbons and having 15 to 18 ethylene oxide units; Fatty alcohols; fatty acid; And mono-, di- and triglycerides of fatty acids. An example of a suitable film-forming coating material for application in liquid techniques is given in GB 1483591. The liquid enzyme preparation is stabilized by adding a polyol such as propylene glycol, sugar, sugar alcohol, lactic acid or boric acid according to established methods, for example. The protected enzyme can be prepared according to the method described in EP 238,216.
    [334] The detergent compositions of the present invention may be in any convenient form, for example, in the form of bars, tablets, powders, granules, doughs or liquids. Liquid detergents are typically aqueous or nonaqueous, including 70% water and 0-30% organic solvents.
    [335] The detergent composition may be non-ionic and include one or more surfactants including anti-polar and / or anionic and / or cationic and / or amphoteric ionic systems. Surfactants are typically present at levels of from 0.1% to 60% by weight.
    [336] When included therein, the detergent typically comprises an anionic surfactant such as from about 1% to about 40% linear alkyl benzene sulfonate, alpha -sulfo fatty acid methyl ester, alkyl- or alkenylsuccinic acid, or soap.
    [337] When included therein, the detergent typically contains from about 0.2% to about 40% of an alcohol ethoxylate, a nonylphenol ethoxylate, an alkylpolyglycoside, an alkyldimethylamine oxide, an ethoxylated fatty acid amide, a fatty acid monoethanolamide, Polyhydroxyalkyl fatty acid amides, or N-acyl N-alkyl derivatives of glucosamine (" glucamide ").
    [338] The detergent may comprise from 0 to 65% of a zeolite, a diphosphate, a triphosphate, a phosphonate, a carbonate, a citrate, nitrilotriacetic acid, ethylenediaminetetraacetic acid, diethylenetriaminepentaacetic acid. An alkyl- or alkenylsuccinic acid, an admixture such as a soluble silicate or a layered silicate (e.g., SKS-6 from Hoechst) or a complexing agent.
    [339] The detergent may contain one or more polymers. Examples include polycarboxylic acids such as carboxymethylcellulose, poly (vinylpyrrolidone), poly (ethylene glycol), poly (vinyl alcohol), poly (vinylpyridine-N-oxide) Malic acid / acrylic acid copolymer, and lauryl methacrylate / acrylic acid copolymer.
    [340] The detergent may contain a bleach system comprising an H 2 O 2 source such as perborate or percarbonate, which may be combined with a peracid-forming bleach activator such as tetraacetylenediamine or phenanthoyloxybenzenesulfonate. Alternatively, the bleach system may include, for example, an amide, imide, or sulfone type peroxy acid.
    [341] Enzymes of the detergent compositions of the present invention may contain conventional stabilizing agents such as polyols such as propylene glycol or glycol, sugars, sugar alcohols, lactic acid, boric acid or boric acid derivatives such as aromatic borate esters, phenylboric acid derivatives of 4-formylphenylborate And the composition can be formulated, for example, as described in WO 92/19709 and WO 92/19708.
    [342] Detergents may also contain other conventional detergent ingredients such as, for example, fabric conditioners including mud, foam promoters, suds inhibitors, anti-corrosives, dyes, antibacterials, optical brighteners, aromatics, color fade inhibitors, can do.
    [343] Some enzymes in the detergent composition, especially the enzymes of the present invention, are added in an amount corresponding to 0.01 to 100 mg enzyme protein per liter of wash liquor, preferably 0.05 to 5 mg enzyme protein per liter of wash liquor, in particular 0.1 to 1 mg enzyme protein per liter of wash liquor It is intended now.
    [344] The enzymes of the present invention may additionally be incorporated into the detergent formulations disclosed in WO 97/07202, which is hereby incorporated by reference.
    [345] Application to leather industry
    [346] The subtilisers of the present invention are used in the leather industry, especially for alopecia of leather.
    [347] In this application, the subtilase mutant of the present invention is preferably used in an enzyme composition further comprising another protease.
    [348] For a more detailed description of other suitable proteases, see the appropriate section for enzymes for detergent composition applications (see above).
    [349] Application to the woolen industry
    [350] The subtilases of the present invention are used in the wool industry, especially for the washing of wool-containing fabrics.
    [351] In this application, the subtilase mutant of the present invention is preferably used in an enzyme composition further comprising another protease.
    [352] For a more detailed description of other suitable proteases, see the appropriate section for enzymes for detergent composition applications (see above).
    [353] The present invention is described in further detail in the following examples, which are not intended to limit the scope of the claimed invention in any way.
    [354] Materials and methods
    [355] Strain :
    [356] B. subtilis DN1885 (Diderichsen et al., 1990).
    [357] B. lentus 309 and 147 are specific strains of Bacillus lentus , deposited with NCIB and assigned accession numbers NCIB 10309 and 10147, and described in U.S. Patent 3,723,250, incorporated herein by reference.
    [358] E. coli MC 1000 (.. MJ Casadaban and SN Cohen (1980); J. Mol Biol 138 179-207) is by conventional methods r -, m + became, are also described in United States Patent 039 298.
    [359] Plasmids :
    [360] pJS3: E. coli-B. subtilis shuttle vector containing the synthetic gene encoding subtilase 309 (Jacob Schiødt et al. Protein and Peptide letters 3: 39-44 (1996)).
    [361] pSX222: B. subtilis expression vector (described in WO 96/34946).
    [362] General molecular biology :
    [363] Unless otherwise noted, DNA manipulation and transformation were performed using standard molecular biology methods (Sambrook et al. (1989) Molecular cloning: A laboratory manual, Cold Spring Harbor lab., Cold Spring Harbor, NY; Ausubel, FM et (eds.) "Current Protocols in Molecular Biology", John Wiley and Sons, 1995; Harwood, CR and Cutting, SM (eds.) "Molecular Biological Methods for Bacillus", John Wiley and Sons, 1990).
    [364] DNA engineering enzymes were used according to supplier specifications.
    [365] DNA engineering enzyme
    [366] Unless otherwise stated, all DNA manipulating enzymes, such as restriction endonucleases, ligases, and the like, are purchased from New England Biolabs, Inc.
    [367] Protein activity
    [368] In the context of the present invention, the proteolytic activity is expressed in kilo NOVO protease units (KNPU). The activity is determined by the enzyme standard (SAVINASE ), And the measurement is based on the hydrolysis of the dimethyl casein (DMC) solution by proteolytic enzyme under standard conditions, i.e., 50 DEG C, pH 8.3, reaction time of 9 minutes, measurement time of 3 minutes. Folder AF 220/1 is available on request from Novo Nordisk A / S, Denmark, which is hereby incorporated by reference.
    [369] GU is a glycine unit defined as a proteolytic enzyme activity that produces an amount of NH 2 - group equivalent to 1 mmole glycine with N-acetyl casein as a substrate at 40 ° C for 15 minutes under standard conditions.
    [370] Enzyme activity also depends on the reaction with the soluble substrate succinyl-alanine-alanine-proline-phenyl-alanine-para-nitro-phenol, And the PNA assay described by Smith, LA, (1988).
    [371] Fermentation :
    [372] Fermentation for the production of the subtilase enzyme is carried out on a rotary shaking table (300 r.p.m.) in a 500 ml Erlenmeyer flask with an obstruction plate containing the BPX medium for 5 days at 30 ° C.
    [373] As a result, for example, 20 Erlenmeyer flasks were fermented simultaneously to produce 2 liters of juice.
    [374] Badge :
    [375] BPX medium composition (per liter)
    [376] Potato starch 100g
    [377] Barley powder 50g
    [378] Soybean powder 20g
    [379] Na 2 HPO 4 x 12H 2 O 9 g
    [380] Fluoron 0.1g
    [381] Sodium caseinate 10 g
    [382] Starch in the medium is liquefied with [alpha] -amylase and the medium is sterilized by heating at 120 [deg.] C for 45 minutes. After sterilization, the medium pH is adjusted to 9 by addition of 0.1M NaHCO 3.
    [383] (Example 1)
    [384] Production and expression of enzyme variants
    [385] Site-specific mutagenesis :
    [386] The subtilase 309 site specific mutation of the present invention comprising a specific insertion between position 96 and 97 in the active site loop (b) is obtained by PCR-generated DNA fragment of oligos containing the desired insert (Sambrook et al. Molecular Cloning: A Laboratory Manual, 2nd Ed. Cold Spring Harbor, 1989) (see below).
    [387] The template plasmid DNA was a derivative thereof containing variants of pJS3 or subtilase 309.
    [388] Insertion was introduced into the preparation of L96LX (X = any amino acid residue inserted between positions 96 and 97) insertion variants by oligo-induced mutagenesis resulting in L96LX subtilase 309 variant.
    [389] Subtilase 309 variants were transformed into E. coli . It is transformed with DNA purified from the overnight culture of the transformants were transformed into B. subtilis by transformation of the purified restriction endonuclease hydrolysis, DNA fragments, ligation, B. subtilis.
    [390] Transformation of B. subtilis is described in Dubnau et al., 1971, J. Mol. Biol. 56, pp. 209-221. ≪ / RTI >
    [391] Ubiquitous random mutagenesis to insert random insertion into ubiquitous regions :
    [392] The overall strategy used to perform ubiquitous random mutagenesis was as follows:
    [393] Mutagenic primers (oligonucleotides) were synthesized which correspond to the DNA sequences flanked at the insertion site and separated by a DNA base pair defining insertion.
    [394] The resulting mutagenic primer was then used in a PCR reaction with a suitable counter primer. The resulting PCR fragment was hydrolyzed by endonuclease and digested with E. coli-B. was purified and extended by a secondary PCR-reaction (see below), prior to cloning into the subtilis shuttle vector.
    [395] Alternatively, if necessary, the resulting PCR fragment may be used as a primer for a second PCR reaction with a second suitable counter primer to permit hydrolysis and cloning of the mutagenized region into a shuttle vector. The PCR reaction is carried out under normal conditions.
    [396] According to this strategy, a ubiquitous random mutagenesis library with insertions in the active site loop region between positions 96 and 97 in SAVINASE was produced.
    [397] Mutations were introduced by mutagenic primers (see below) such that all 20 amino acids were present (N = 25% A, T, C and G, S = 50% C and G). The resulting PCR fragment contained primers; 5 'CTA AAT ATT CGT GGT GGC GC 3' (sense) and 5 'GAC TTT AAC AGC GTA TAG CTC AGC 3' (antisense) Terminal direction of Savinase by the PCR cycle of < RTI ID = 0.0 > The extended DNA-fragment was cloned into the HindIII- and MluI- sites of the modified plasmid pJS3 (see above) and sequenced ten randomly selected E. coli colonies to identify the designed mutation.
    [398] (5 ' GCT GAG CTA TAC GCT GTT AAA GTC CTA NNS GGG GCG AGC GGT TCA GGT TC 3 ' (Sense)) is inserted into the plasmid pJS3 with a suitable antisense counterpart primer '- CCC TTT AAC CGC ACA GCG TTT -3' (antisense)) was used for the PCR reaction with the plasmid pJS3 as template. The resulting PCR product was cloned into the pJS3 shuttle vector by the use of restriction enzymes HindIII and MluI.
    [399] Random libraries were transformed into E. coli by well known techniques.
    [400] The prepared library contained approximately 100,000 individual clones per library.
    [401] Randomly selected colonies were sequenced to identify the designed mutations.
    [402] In order to purify the subtilase variants of the present invention, the B. subtilis pJS3 expression plasmid containing the mutant of the present invention was transformed into a competent B. subtilis strain and cultured in a medium containing 10 μg / ml chloramphenicol (CAM) And fermented as described above.
    [403] (Example 2)
    [404] Purification of enzyme variants :
    [405] This process involves the purification of a 2 liter scale fermentation for the production of the subtilase of the present invention in Bacillus sperm cells.
    [406] Approximately 1.6 liters of fermentation broth was centrifuged in a 1 liter beaker at 5000 rpm for 35 minutes. The supernatant was adjusted to pH 6.5 using 10% acetic acid and filtered on a Seitz Supra S100 filter plate.
    [407] The filtrate was concentrated to approximately 400 ml using an Amicon CH2A UF unit equipped with an Amicon S1Y10 UF cartridge. The UF concentrate was centrifuged and filtered through a Bacitracin affinity column prior to absorption at room temperature, pH 7. The protease was eluted from the Bacitracin column at room temperature using 25% 2-propanol and 1M sodium chloride in a buffer containing 0.01 M dimethylglutaric acid, 0.1 M boric acid and 0.002 M calcium chloride and adjusted to pH 7. [
    [408] The fractions with protease activity from the Bacitracin purification step were combined and applied to a 750 ml Sephadex G25 column (5 cm diameter) equilibrated with a buffer containing 0.01 M dimethylglutaric acid, 0.2 M boric acid and 0.002 M calcium chloride adjusted to pH 6.5 Respectively.
    [409] The fraction with proteolytic activity from the Sephadex G25 column was combined with 150 ml of CM Sepharose CL 6B cation exchange resin equilibrated with a buffer containing 0.01 M dimethylglutaric acid, 0.2 M boric acid and 0.002 M calcium chloride adjusted to pH 6.5 in combination Column (5 cm diameter).
    [410] The protease was eluted using a 0 to 0.1 M sodium chloride linear gradient (0 to 0.2 M sodium chloride in the case of subtilisin 147) in 2 liters of the same buffer.
    [411] The protease containing fractions from the CM Sepharose column in the final purification step were combined and concentrated in an Amicon ultracentrifuge unit equipped with a GR81PP membrane (from Danish Sugar Factories Inc.).
    [412] The following subtilisin 309 variants were produced and isolated using the preparation of Example 1, the fermentation technique and the separation step:
    [413] L96LT
    [414] L96LS
    [415] L96LD
    [416] L96LE
    [417] L96LP
    [418] L96LG
    [419] L96LH
    [420] L96LI
    [421] L96LA
    [422] L96LG
    [423] L96LA + A98T
    [424] L96L + Y167A
    [425] L96LG + G100S
    [426] L96LG + G100S
    [427] L96LG + A98T + Y176A
    [428] L96LG + A98T + S103T
    [429] L96LA + A98T + A194P
    [430] L96LG + S99T + S101A
    [431] L96LG + G100S + Y167A
    [432] N76D + L96LA + A98T
    [433] L96L + A98G + S99G + S101T + S103T
    [434] These mutants showed better wash performance than Savinase in the preliminary analysis.
    [435] (Example 3)
    [436] Cleaning performance of detergent compositions containing enzyme variants
    [437] The following examples provide results from a number of wash tests performed under the indicated conditions.
    [438] Small scale cleaning
    [439] Cleaning conditions:
    [440] EuropeDetergent 95United States of America Detergent dose4 g / l3 g / l1 g / l Cleaning temperature30 ℃15 ℃25 ℃ Washing time30 minutes15 minutes10 minutes Water hardness18 ° dH (Ca 2+ / Mg 2+ = 5: 1)6 ° dH6 ° dH (Ca 2+ / Mg 2+ = 2: 1) pHNo adjustment10.5No adjustment Enzyme concentration1, 2, 5, 10, 30, nM 1, 2, 5, 10, 30, nM Test system150 ml glass beaker with stir bar10 nm150 ml glass beaker with stir bar Fabric / VolumeFive pieces of fabric in a 50ml detergent (Ø2.5cm)Five pieces of fabric in a 50ml detergent (Ø2.5cm)Five pieces of fabric in a 50ml detergent (Ø2.5cm) Test substanceEMPA116EMPA117EMPA117
    [441] Detergent:
    [442] The detergents used were model detergents, designated Detergent 95, or were purchased from Denmark (OMO, Data Sheet ED-9745105) and supermarkets from the United States (Wisk, Data Sheet ED-9711893). All enzyme activities in detergent were inactivated by microwave treatment before use.
    [443] Detergent 95 is a simple model preparation. The pH is adjusted to 10.5, which is within the normal range for the powder detergent. The composition of model detergent 95 is as follows:
    [444] 25% STP (Na 2 P 3 O 10)
    [445] 25% Na 2 SO 4
    [446] 10% Na 2 CO 3
    [447] 20% LAS (Nansa 80S)
    [448] 5.0% non ionic tenside (Dobanol 25-7)
    [449] 5.0% Na 2 Si 2 O 5
    [450] 0.5% carboxymethylcellulose (CMC)
    [451] 9.5% water
    [452] Sample:
    [453] The samples used were EMPA Testmaterialen, Movenstrasse 12, CH-9015 St. EMPA116 and EMPA117 purchased from Gall, Switzerland.
    [454] reflectivity
    [455] Measurement of the reflectance (R) on the test material was performed using a Macbeth ColorEye 7000 optical meter at 460 nm. Measurements were performed according to the manufacturer's protocol.
    [456] evaluation
    [457] The evaluation of the wash performance of the subtilase is determined by the improvement coefficient or performance coefficient for the observed subtilase.
    [458] The improvement factor, IF dose / reaction, is defined as the ratio of the slope of the cleaning performance to the detergent containing the subtilase and the detergent containing the reference subtillase observed at the point where the concentration of the subtilase asymptotes to zero.
    [459] IF Dose / Reaction = a / a ref
    [460] The cleaning ability is expressed by Equation I:
    [461] R = R 0 + a · ΔR max · c / (ΔR max + a · c) (I)
    [462] , Where < RTI ID = 0.0 >
    [463] R is the cleaning performance in reflection units; R 0 is the Y intercept of the curve; a is the slope of the curve when c → 0; c is the enzyme concentration; ΔR max is the theoretical maximum washability when c → ∞.
    [464] Performance factor, and P is equation II:
    [465] P = (R variant- R blank ) / (R Savinase- R blank )
    [466] , Where < RTI ID = 0.0 >
    [467] R mutant is the reflectance of the test substance washed with 10 nM mutants; R Savinase is the reflectance of the test material washed with 10 nM Savinase; The R blank is the reflectance of the test material washed without enzyme.
    [468] Model Cleaner 95
    [469] MutantP L96LG + A98G + S99G + S101T + S103T1.3 L96LG + S99T + S101A1.2 L96LG + A98T + S103T1.3
    [470] US (Detergent: US Wisk, Swatch: EMPA117)
    [471] MutantP L96LG1.7 L96LA1.4 L96LG1.4 L96LT1.5 L96LA + A98T2.2 L96LG + G100S1.8 L96LG + Y167A2 L96LA + A98T1.3 L96LG + A98T + S103T1.3 L96LA + A98T + A194P1.2 L96LG + S99T + S101A1.2 N76D + L96LA + A98T1.3 L96LG + A98G + S99G + S101T + S103T1.7
    [472] The subtilase of the present invention can thus be used as a < RTI ID = Which is an improvement of the cleaning ability.
    权利要求:
    Claims (34)
    [1" claim-type="Currently amended] Characterized in that the additional amino acid residue corresponds to the insertion of at least one amino acid residue between positions 96 and 97, by having at least one additional amino acid residue at position 96 of the active site loop (b) region of positions 95 to 103 Subtilase enzymes of subgroups I-S1 and I-S2.
    [2" claim-type="Currently amended] 2. The isolated subtilase enzyme of claim 1, wherein the subtilase enzyme is a prepared variant having at least one inserted amino acid residue between positions 96 and 97 of the precursor subtilase.
    [3" claim-type="Currently amended] The method of claim 1 or 2, wherein X96X {A, T, G, S}, X96X {D, E, K, R}, X96X {H, V, C, N, Q} , L, M, P, W, Y}. ≪ / RTI >
    [4" claim-type="Currently amended] 4. The isolated subtilase enzyme according to claim 3, wherein said at least one additional or inserted amino acid residue is selected from the group comprising T, G, A,
    [5" claim-type="Currently amended] 4. The method of claim 3 wherein said at least one additional or inserted amino acid residue is selected from the group of charged amino acid residues comprising D, E, H, K and R, more preferably D, E, K and R Lt; RTI ID = 0.0 > subtilase < / RTI > enzyme.
    [6" claim-type="Currently amended] 4. The composition of claim 3 wherein said at least one additional or inserted amino acid residue is selected from the group of hydrophilic amino acid residues comprising C, N, Q, S and T, more preferably N, Q, S and T A discrete subtilase enzyme characterized.
    [7" claim-type="Currently amended] 4. The isolated subtilase enzyme according to claim 3, wherein said at least one additional or inserted amino acid residue is selected from the group of small hydrophobic amino acid residues comprising A, G and V.
    [8" claim-type="Currently amended] 4. The method of claim 3, wherein the at least one additional or inserted amino acid residue is selected from the group consisting of a large hydrophobic character including F, I, L, M, P, W and Y, more preferably F, I, ≪ / RTI > amino acid residues of the subtilase enzyme.
    [9" claim-type="Currently amended] 9. The method according to any one of claims 1 to 8, wherein the at least one additional or inserted amino acid residue comprises more than one additional or inserted amino acid residue in the active site loop (b) Isolated subtilase enzyme.
    [10" claim-type="Currently amended] 10. The subtilase variant according to any one of claims 1 to 9, wherein said insertion between positions 96 and 97 is combined with one or more further modifications at other arbitrary positions.
    [11" claim-type="Currently amended] The method of claim 10, wherein the further strain is at least one of positions 27, 36, 57, 76, 87, 97, 101, 104, 120, 123, 167, 170, 206, 218, 222, 224, 235, ≪ / RTI > or a subtilase variant thereof.
    [12" claim-type="Currently amended] 12. The subtilase variant according to any one of claims 1 to 11, wherein said variant is combined with a modification at one or more of positions 129, 131, 133 and 194.
    [13" claim-type="Currently amended] 13. The subtilase according to any one of claims 1 to 12, wherein the subtilase or the subtilase belongs to subgroup I-S1 when the subtilase is a mutant.
    [14" claim-type="Currently amended] 14. The subtilase according to claim 13, wherein the subtilase is selected from the group comprising ABSS168, BASBPN, BSSDY, and BLSCAR or their functional variants maintaining the characteristics of subgroup I-S1.
    [15" claim-type="Currently amended] 15. The subtilase according to any one of claims 1 to 14, wherein the subtilase or the subtilase belongs to subgroup I-S2 when the subtilase is a mutant.
    [16" claim-type="Currently amended] 16. The subtilase of claim 15, wherein the subtilase is selected from the group comprising BLS147, BLS309, BAPB92, TVTHER, and BYSYAB or a functional variant thereof that retains the characteristics of subgroup I-S2.
    [17" claim-type="Currently amended] 17. The method of claim 3, 15 or 16,
    L96LA,
    L96LT,
    L96LG,
    L96LS,
    L96LD,
    L96LE,
    L96LK,
    L96LR,
    L96LH,
    L96LV,
    L96LC,
    L96LN,
    L96LQ,
    L96LF,
    L96LI,
    L96LL,
    L96LM,
    L96LP,
    L96LW, and
    L96LY
    ≪ / RTI > wherein said subtilase enzyme is selected from the group consisting of: < RTI ID = 0.0 >
    [18" claim-type="Currently amended] A method as claimed in any one of claims 15 to 17, wherein said further variant is selected from the group consisting of K27R, * 36D, S57P, N76D, S87N, G97N, S101G, V104A, V104N, V104Y, H120D, N123S, Y167X, R170X, Q206E, N218S, M222S, M222A, T224S, K235L and T274A.
    [19" claim-type="Currently amended] 18. The method according to any one of claims 15 to 17, wherein said further variant is selected from the group consisting of S101G + V104N, S87N + S101G + V104N, K27R + V104Y + N123S + T274A, N76D + S103A + V104I or N76D + V104A, (V104N, S101G, K27R, V104Y, N123S, T274A, N76D, V104A) is combined with one or more substitutions, deletions and / or insertions mentioned in any one of claims 1 to 14 ≪ / RTI > or a subtilase variant thereof.
    [20" claim-type="Currently amended] 18. The subtilase variant according to any one of claims 15 to 17, wherein said further variant is selected from the group further comprising P129K, P131H, A133P, A133D and A194P.
    [21" claim-type="Currently amended] 21. The method according to any one of claims 1 to 20, wherein L96LA + A98T, L96LG + G100S, L96LG + Y167A, L96LA + A98T, L96LG + A98T + S103T, L96LG + A98T + Y167A, L96LG + S99T + S101A, L96LG + A variant selected from the group comprising S100S + Y167A, L96LA + A98T + A194P, N76D + L96LA + A98T, L96LG + A98G + S99G + S191T + S103T.
    [22" claim-type="Currently amended] Amino acid sequence:
    1 10 20 30
    V-P-Y-G-I-P-L-I-K-A-D-K-V-Q-A-Q-G-F-K-
    40 50 60
    L-D-T-G-I-Q-A-S-H-P-D-L-N-V-G-G-A-S-F-V-A-
    70 80 90
    G-N-G-H-G-T-H-V-A-G-T-V-A-A-L-D-N-T-G-V-L-
    96a 110 120
    Y-A-V-K-V-L-X-N-S-S-G-S-G-T-Y-S-G-I-V-S-G-I-E-W-A-T-
    130 140 150
    V-I-N-M-S-L-G-G-P-S-G-S-T-A-M-K-Q-A-V-D-N-A-Y-A-R-G-V-V-V
    160 170 180
    A-A-G-N-S-G-S-S-G-N-T-N-T-I-G-Y-P-A-K-Y-D-S-V-I-A-V-G-A-V
    190 200 210
    D-S-N-S-N-R-A-S-F-S-S-V-G-A-E-L-E-V-M-A-
    220 230 240
    T-S-T-Y-A-T-L-N-G-T-S-M-A-S-P-H-V-A-G-A-A-A-L-I-
    250 260 270
    L-S-A-S-Q-V-R-N-R-L-S-S-T-A-T-Y-L-G-S-S-F-Y-Y-G-
    275
    E-A-A-A-Q
    Or 75%, 80%, 85%, 90%, 95% identity with said sequence with an amino acid sequence comprising the amino acid residue at position 96a, or a subtilase belonging to subgroup I-S Homologous subtilase.
    [23" claim-type="Currently amended] Amino acid sequence:
    1 10 20 30
    V-P-W-G-I-S-R-V-Q-A-P-A-H-
    40 50 60
    D-T-G-I - * - S-T-H-P-D-L-N-I-R-G-
    70 80 90
    G-N-G-H-G-T-H-V-A-G-T-I-A-A-L-N-N-S-
    96a 110 120
    Y-A-V-K-V-L-X-G-A-S-G-S-G-S-V-S-
    130 140 150
    V-A-N-L-S-L-G-S-P-S-P-S-A-T-
    160 170 180
    A-S-G-N-S-G-A-G-S-I-S-
    190 200 210
    D-Q-N-N-N-R-A-S-F-S-Q-Y-G-A-
    220 230 240
    G-S-T-Y-A-S-L-N-G-T-S-M-A-T-P-H-
    250 260 270
    W-S-N-V-Q-I-R-N-H-L-K-N-T-A-T-S-
    275
    E-A-A-T-R
    , Or an amino acid sequence comprising an amino acid residue at position 96a and having an identity of greater than 70%, 75%, 80%, 85%, 90%, or 95% with the sequence, or a subtilase belonging to subgroup I- Homologous subtilase.
    [24" claim-type="Currently amended] 23. The subtilase variant according to claim 22 or 23, wherein X in position 96a is selected from the group comprising T, A, G, S and P.
    [25" claim-type="Currently amended] 24. A isolated DNA sequence encoding a subtilase or a subtilase variant of any one of claims 1 to 24.
    [26" claim-type="Currently amended] 26. An expression vector comprising the isolated DNA sequence of claim 25.
    [27" claim-type="Currently amended] 26. A microbial host cell transformed with the expression vector of claim 26.
    [28" claim-type="Currently amended] 28. The microbial host cell of claim 27, wherein the microbial host cell is a bacterium, preferably Bacillus , especially Bacillus lentus .
    [29" claim-type="Currently amended] 28. The microbial host cell according to claim 27, wherein the microbial host cell is a fungus or a yeast, preferably a filamentous fungus, especially Aspergillus .
    [30" claim-type="Currently amended] 29. A method for producing the subtilase or subtilase variant of any one of claims 1 to 24 wherein the host of any one of claims 27 to 29 is administered under conditions that favor the expression and secretion of the variant ≪ / RTI > is cultured and the variants are recovered.
    [31" claim-type="Currently amended] 24. A composition comprising a subtilase or a subtilase variant according to any one of claims 1 to 24.
    [32" claim-type="Currently amended] 32. The composition of claim 31, further comprising a cellulase, a lipase, a quinidine, an oxidoreductase, another protease or an amylase.
    [33" claim-type="Currently amended] 33. The composition of claim 31 or 32, wherein the composition is a detergent composition.
    [34" claim-type="Currently amended] Use of a subtilase or a subtilase variant according to any one of claims 1 to 24, or an enzyme composition according to claims 31 or 32 in a washing and / or dishwashing detergent.
    类似技术:
    公开号 | 公开日 | 专利标题
    RU2710720C2|2020-01-10|Subtilase variants and polynucleotides encoding same
    JP6054615B2|2016-12-27|Subtilase variant
    JP5412522B2|2014-02-12|Compositions and methods comprising subtilisin variants
    JP5806255B2|2015-11-10|subtilase variant
    RU2560978C2|2015-08-20|Proteases comprising one or more combinable mutations
    CA2419896C|2014-12-09|Subtilase enzymes
    ES2381539T3|2012-05-29|New alkaline protease from Bacillus SP. | and detergents or cleaning agents containing this new alkaline protease
    JP4819670B2|2011-11-24|Mutant subtilisin enzyme |
    EP0824585B1|2009-04-22|Protease variants and compositions
    CA2062732C|2000-05-23|A mutated subtilisin protease
    US6908991B2|2005-06-21|Useful mutations of bacterial alkaline protease
    US5858757A|1999-01-12|Stabilized enzymes and detergent compositions
    FI119697B|2009-02-13|Subtilis variants
    US5665587A|1997-09-09|Modified subtilisins and detergent compositions containing same
    CA2270180C|2011-01-11|Subtilase variants and compositions
    CA2301851C|2012-08-07|Protease variants and compositions
    EP2558573B1|2017-02-22|Compositions and methods comprising variant proteases
    EP1456366B1|2012-01-18|Novel alkali protease formed by bacillus gibsonii | and washing and cleaning agents containing said novel alkali protease
    JP4028592B2|2007-12-26|High alkaline serine protease
    EP0405901B1|2004-09-01|Enzymatic detergent compositions
    JP4050654B6|2007-12-07|Stabilizing enzymes and detergents
    US10351837B2|2019-07-16|Subtilase variants
    EP0516200B1|1996-07-24|Detergent compositions containing stabilized enzymes
    CA2310454C|2012-01-24|Protease variants and compositions
    CA2270593C|2005-06-07|Subtilase variants and compositions
    同族专利:
    公开号 | 公开日
    AT371023T|2007-09-15|
    BRPI9916352B1|2016-04-19|
    WO2000037623A1|2000-06-29|
    EP1141258A1|2001-10-10|
    KR100660806B1|2006-12-26|
    AU1772700A|2000-07-12|
    BR9916352A|2001-09-18|
    DE69936933D1|2007-10-04|
    DE69936933T2|2008-05-15|
    CA2355655C|2011-03-15|
    AU773063B2|2004-05-13|
    CN101275127B|2013-02-06|
    JP2002533076A|2002-10-08|
    CA2355655A1|2000-06-29|
    CN101275127A|2008-10-01|
    EP1141258B1|2007-08-22|
    CN1333826A|2002-01-30|
    JP4647787B2|2011-03-09|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    法律状态:
    1998-12-18|Priority to DKPA199801675
    1998-12-18|Priority to DKPA199801675
    1999-12-20|Application filed by 피아 스타르, 노보자임스 에이/에스
    2001-10-27|Publication of KR20010093171A
    2006-12-26|Application granted
    2006-12-26|Publication of KR100660806B1
    优先权:
    申请号 | 申请日 | 专利标题
    DKPA199801675|1998-12-18|
    DKPA199801675|1998-12-18|
    [返回顶部]